Compare Mesoblast Limited (MESO) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs ProShares UltraPro Short QQQ ETF — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while ProShares UltraPro Short QQQ ETF trades at $32.95 (market cap $2.23B). The key difference: ProShares UltraPro Short QQQ ETF is the larger of the two by market cap, and Mesoblast Limited is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and ProShares UltraPro Short QQQ ETF for 12 Days on average.
| MESO | SQQQ | |
|---|---|---|
Market Cap | $1.75B | $2.23B |
Volume | 239,027 | 60,436,012 |
Sector | Health | Leveraged / Inverse |
52-Week High | $20.96 | $89.43 |
52-Week Low | $13.19 | $31.83 |
Typical Hold Time | 15 Days | 12 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
SQQQ (ProShares UltraPro Short QQQ) trades at $33.37, up 4.02% today, reflecting its bearish positioning against the Nasdaq 100. Technical indicators show a predominantly bearish signal with moving averages indicating selling pressure, while oscillators remain neutral. The ETF serves as a leveraged short tool for hedging QQQ exposure, with recent news highlighting its strategic use in portfolio protection amid tech sector volatility.
The outlook for SQQQ remains tied to Nasdaq 100 performance, offering potential gains during market downturns but carrying high risk due to daily rebalancing and decay. Key risks include rapid market reversals and the structural challenges of leveraged inverse ETFs. Investor sentiment is cautious, with media coverage emphasizing its role as a hedging instrument rather than a long-term hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
